[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Companion Diagnostics for Oncology Market: Information By Products & Services (Assays, Kits & Reagents and Software & Services), Technology (Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Melanoma), End User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Laboratories) - Forecast till 2030

December 2021 | 179 pages | ID: CE4C7BF4B781EN
Fatpos Global

US$ 5,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Market Overview
Fatpos Global has released a report titled Companion Diagnostics for Oncology Market - Analysis of Market Size, Share & Trends for 2014 - 2020 and Forecasts to 2031. According to a study by Fatpos Global, is anticipated to reachUSD 1,603.16 Million in 2019 and is expected to register a CAGR of 22.57% during the forecast period of 2020 to 2030.

. According to the report, emphasizes on the detailed understanding of some decisive factors such as size, share, sales, forecast trends, supply, production, demands, industry and CAGR in order to provide a comprehensive outlook of the global market

Companion Diagnostics for Oncology Market Market: Key Players

Technologies Inc.
, Illumina,
Inc.,
F. Hoffmann-La Roche Ltd,
BioM?rieux SA,
Foundation Medicine,
Archer Dx, Qiagen,
Thermo Fisher Scientific Inc.
, Amoy Dx,
and Abbott.

Segmentation
Market Segmentation

Companion Diagnostics for Oncology Market, By Products & Services

Assays, Kits & Reagents
Software & Services
Companion Diagnostics for Oncology Market, By Technology

Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Companion Diagnostics for Oncology Market, By Indication

Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Companion Diagnostics for Oncology Market, By End User

Pharmaceutical & Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
Companion Diagnostics for Oncology Market, By Region

Americas
North America
US
Canada
Latin America
Europe
Western Europe
Germany
UK
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
Middle East
Africa
Available Additional Customizations

Additional 5 Company Profiles
Intended Audience

Medical device companies
Contract research organizations
Research & development organizations
Academic institutes


Companion Diagnostics for Oncology Market Market Dynamics
Companion Diagnostics for Oncology Market Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Companion Diagnostics for Oncology Market Market growth?
Which segment accounted for the largest Companion Diagnostics for Oncology Market Market share?
Who are the key players in the Griddles Market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
1. EXECUTIVE SUMMARY

2. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET

2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. RESEARCH METHODOLOGY

3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. AVERAGE PRICING ANALYSIS

5. MACRO-ECONOMIC INDICATORS

6. MARKET DYNAMICS

6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7. CORRELATION & REGRESSION ANALYSIS

7.1. Correlation Matrix
7.2. Regression Matrix

8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE

9. RISK ANALYSIS

9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS

10.1. Porters Five Forces
  10.1.1. Threat of New Entrants
  10.1.2. Bargaining Power of Suppliers
  10.1.3. Threat of Substitutes
  10.1.4. Rivalry
10.2. PEST Analysis
  10.2.1. Political
  10.2.2. Economic
  10.2.3. Social
  10.2.4. Technological

11. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET

11.1. Market Size & forecast, 2020A-2030F
  11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET: MARKET SEGMENTATION

12.1. By Regions
  12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By network type: Market Share (2020-2030F)
  12.2.1. Hardware , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.2.2. Software , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.2.3. Services , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By End user: Market Share (2020-2030F)
  12.3.1. Manufacturing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.2. Healthcare, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.3. Energy and Utilities, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.4. IT & Telecom, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.5. Automotive and Transportation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.6. Supply Chain and Logistics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.7. Government and Public Safety, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.8. Agriculture, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12.3.9. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
Company Profile
Technologies Inc.
, Illumina,
Inc.,
F. Hoffmann-La Roche Ltd,
BioM?rieux SA,
Foundation Medicine,
Archer Dx, Qiagen,
Thermo Fisher Scientific Inc.
, Amoy Dx,
and Abbott.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.


More Publications